Wall Street analysts expect Eli Lilly And Co (NYSE:LLY) to announce $6.07 billion in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Eli Lilly And Co’s earnings, with the highest sales estimate coming in at $6.14 billion and the lowest estimate coming in at $6.00 billion. Eli Lilly And Co posted sales of $5.66 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 7.2%. The company is scheduled to report its next earnings results on Tuesday, October 23rd.

According to Zacks, analysts expect that Eli Lilly And Co will report full-year sales of $24.45 billion for the current financial year, with estimates ranging from $24.41 billion to $24.51 billion. For the next fiscal year, analysts forecast that the business will report sales of $25.03 billion, with estimates ranging from $24.89 billion to $25.12 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Eli Lilly And Co.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 EPS for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion during the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 earnings per share.

A number of research firms have recently commented on LLY. Barclays restated an “overweight” rating and issued a $112.00 price objective (up from $107.00) on shares of Eli Lilly And Co in a research report on Tuesday, September 18th. Cantor Fitzgerald set a $110.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Monday, September 17th. TheStreet cut Eli Lilly And Co from a “b” rating to a “c+” rating in a research report on Friday, August 24th. ValuEngine upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Finally, Morgan Stanley boosted their price target on Eli Lilly And Co from $93.00 to $102.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 31st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $101.00.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $106.31, for a total transaction of $637,860.00. Following the transaction, the senior vice president now owns 55,224 shares of the company’s stock, valued at $5,870,863.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 170,000 shares of the business’s stock in a transaction on Thursday, July 5th. The stock was sold at an average price of $86.62, for a total value of $14,725,400.00. Following the transaction, the insider now directly owns 121,880,804 shares in the company, valued at approximately $10,557,315,242.48. The disclosure for this sale can be found here. Insiders have sold 1,706,944 shares of company stock valued at $167,978,247 over the last quarter. 0.11% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Franklin Resources Inc. boosted its stake in Eli Lilly And Co by 14.1% during the first quarter. Franklin Resources Inc. now owns 32,541,775 shares of the company’s stock worth $2,517,762,000 after buying an additional 4,022,251 shares during the last quarter. Schroder Investment Management Group lifted its stake in shares of Eli Lilly And Co by 103.8% in the 1st quarter. Schroder Investment Management Group now owns 4,689,223 shares of the company’s stock valued at $362,806,000 after purchasing an additional 2,388,548 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Eli Lilly And Co by 3.0% in the 1st quarter. BlackRock Inc. now owns 65,780,446 shares of the company’s stock valued at $5,089,436,000 after purchasing an additional 1,926,334 shares during the last quarter. Morgan Stanley lifted its stake in shares of Eli Lilly And Co by 37.8% in the 2nd quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock valued at $381,727,000 after purchasing an additional 1,227,888 shares during the last quarter. Finally, Investec Asset Management LTD lifted its stake in shares of Eli Lilly And Co by 49.6% in the 2nd quarter. Investec Asset Management LTD now owns 2,528,279 shares of the company’s stock valued at $215,738,000 after purchasing an additional 838,271 shares during the last quarter. 76.51% of the stock is currently owned by institutional investors.

Shares of Eli Lilly And Co stock traded up $0.11 on Tuesday, reaching $105.70. The company’s stock had a trading volume of 3,712,200 shares, compared to its average volume of 4,138,327. The stock has a market capitalization of $114.20 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 1.86 and a beta of 0.27. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $107.84. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Why do companies issue stock splits?

Get a free copy of the Zacks research report on Eli Lilly And Co (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.